Adoptive immunotherapy with CMV-specific cytotoxic T lymphocytes for stem cell transplant patients with refractory CMV infections

Journal of Immunotherapy

Volumn 35, Issue 3, 2012, Pages 293-298

  Bao, Lei ^a   Cowan, Morton J ^b   Dunham, Kimberly ^a   Horn, Biljana ^b   McGuirk, Joseph ^c   Gilman, Andrew ^d   Lucas, Kenneth G ^a  

^a PENN STATE CHILDREN S HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^d Levine Children's Hospital   (United States)

Author keywords

CTL; cytomegalovirus; IE1; immunotherapy; pp65

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN A;

ADOPTIVE IMMUNOTHERAPY; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CELL VIABILITY; CHILD; CLINICAL ARTICLE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; INFANT; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; VIRUS REACTIVATION;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INFANT; STEM CELL TRANSPLANTATION; T-LYMPHOCYTES, CYTOTOXIC; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84858755419     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0b013e31824300a2     Document Type: Article

References (22)

1. Salzberger B, Bowden RA, Hackman RC, et al. Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease: risk factors and outcome. Blood. 1997;90:2502-2508. (Pubitemid 27392736)
2. Battiwalla M, Wu Y, Bajwa RP, et al. Ganciclovir inhibits lymphocyte proliferation by impairing DNA synthesis. Biol Blood Marrow Transplant. 2007;13:765-770. (Pubitemid 46902442)
3. Goodrich JM, Bowden RA, Fisher L, et al. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med. 1993;118:173-178. (Pubitemid 23034801)
4. Riddell SR, Greenberg PD. Principles for adoptive T cell therapy of human viral diseases. Annu Rev Immunol. 1995;13:545-586.
5. Boeckh M, Gooley TA, Myerson D, et al. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood. 1996; 88:4063-4071. (Pubitemid 26383133)
6. Biron KK. Antiviral drugs for cytomegalovirus diseases. Antiviral Res. 2006;71:154-163. (Pubitemid 44223768)
7. Leen AM, Christin A, Myers GD, et al. Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation. Blood. 2009;114:4283-4292.
8. Riddell SR, Watanabe KS, Goodrich JM, et al. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science. 1992;257:238-241.
9. Einsele H, Roosnek E, Rufer N, et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood. 2002;99:3916-3922. (Pubitemid 35332029)
10. Peggs KS, Verfuerth S, Pizzey A, et al. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet. 2003;362: 1375-1377. (Pubitemid 37338339)
11. Cobbold M, Khan N, Pourgheysari B, et al. Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J Exp Med. 2005;202:379-386. (Pubitemid 41126955)
12. Micklethwaite K, Hansen A, Foster A, et al. Ex vivo expansion and prophylactic infusion of CMV-pp65 peptide-specific cytotoxic T-lymphocytes following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2007;13:707-714. (Pubitemid 46767999)
13. Bao L, Sun Q, Lucas KG. Rapid generation of CMV pp65-specific T cells for immunotherapy. J Immunother. 2007;30: 557-561. (Pubitemid 46988089)
14. Horn B, Bao L, Dunham K, et al. Infusion of cytomegalovirus specific cytotoxic T lymphocytes from a sero-negative donor can facilitate resolution of infection and immune reconstitution. Pediatr Infect Dis J. 2009;28:65-67.
15. Schultze JL, Michalak S, Seamon MJ, et al. CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J Clin Invest. 1997;100: 2757-2765. (Pubitemid 28007544)
16. Sun Q, Burton RL, Dai LJ, et al. B lymphoblastoid cell lines as efficient APC to elicit CD8+ T cell responses against a cytomegalovirus antigen. J Immunol. 2000;165:4105-4111. (Pubitemid 32057322)
17. Bao L, Dunham K, Stamer M, et al. Expansion of cytomegalovirus pp65 and IE-1 specific cytotoxic T lymphocytes for cytomegalovirus-specific immunotherapy following allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2008;14:1156-1162.
18. Zhan X, Brown B, Slobod KS, et al. Inhibition of ex vivoexpanded cytotoxic T-lymphocyte function by high-dose cyclosporine. Transplantation. 2003;76:739-740.
19. Peggs KS, Mackinnon S. Augmentation of virus-specific immunity after hematopoietic stem cell transplantation by adoptive T-cell therapy. Hum Immunol. 2004;65:550-557. (Pubitemid 38686780)
20. Thomson K, Julie M, Pang K, et al. Direct isolation of donorderived antigen-specific T cells and their adoptive transfer for treatment or prophylaxis of CMV infection following allogeneic transplantation. Blood. 2006;108:177a.
21. Waldrop SL, Pitcher CJ, Peterson DM, et al. Determination of antigen-specific memory/effector CD4+ T cell frequencies by flow cytometry: evidence for a novel, antigen-specific homeostatic mechanism in HIV-associated immunodeficiency. J Clin Invest. 1997;99:1739-1750. (Pubitemid 27163826)
22. Brown DM. Cytolytic CD4 cells: direct mediators in infectious disease and malignancy. Cell Immunol. 2010;262:89-95.